Lipids & metabolic liver disease

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials

Diabetes Obes MetabPublished Post hoc analysis of three randomised controlled trials

Authors' conclusion

People with MASLD/MASH had similar semaglutide-mediated weight loss regardless of type 2 diabetes status and other cardiometabolic risk parameters.

Study context

Population
Adults with MASLD or biopsy-confirmed MASH, with T2D, pre-T2D or no diabetes3 RCTs pooled · with T2D 209 · pre-T2D 51 · or no diabetes 40
Participants
163 vs 137
Comparison
Semaglutide vs placebo
  • Semaglutiden = 163
  • Placebon = 137reference
Primary endpoint
Weight change by T2D status
Follow-up
1 year
Methodological detailspooled analysis, placebo-controlled, 48-72-week trials, subgroup analysis by type 2 diabetes status
  • Pooled analysis
  • Placebo-controlled
  • 48-72-week trials
  • Subgroup analysis by type 2 diabetes status

Primary result

As reported in the abstract

Estimated treatment difference in weight change by T2D status

Estimated treatment difference (T2D)

−10.2 kg

−10.8%

Estimated treatment difference (pre-T2D)

−9.8 kg

−10.2%

Estimated treatment difference (no diabetes)

−11.6 kg

−13.1%

Differences between subgroups not statistically significant
P > 0.50 for all

Further findings

OutcomeSemaglutidePlacebo
Overall mean weight change · 1 yearkg−11.1−0.7
Percent change−11.7%−0.6%

Correlation of baseline cardiometabolic parameters with weight change

Baseline FPG, HbA1c, insulin, insulin resistance and lipids did not correlate with weight change

Original publication

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials. Diabetes Obes Metab. Published 28 November 2024. doi:10.1111/dom.16065

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.